Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandResearch in context

• Main Authors: Paul Thoueille (Author), Susana Alves Saldanha (Author), Fabian Schaller (Author), Eva Choong (Author), Aline Munting (Author), Matthias Cavassini (Author), Dominique Braun (Author), Huldrych F. Günthard (Author), Katharina Kusejko (Author), Bernard Surial (Author), Hansjakob Furrer (Author), Andri Rauch (Author), Mathieu Rougemont (Author), Pilar Ustero (Author), Alexandra Calmy (Author), Marcel Stöckle (Author), Catia Marzolini (Author), Caroline Di Benedetto (Author), Enos Bernasconi (Author), Patrick Schmid (Author), Rein Jan Piso (Author), Pascal Andre (Author), François R. Girardin (Author), Monia Guidi (Author), Thierry Buclin (Author), Laurent A. Decosterd (Author)
• Format: Book
• Published: Elsevier, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: The efficacy and tolerability of long-acting cabotegravir and rilpivirine were demonstrated in Phase III trials. However, low concentrations combined with other risk factors have been associated with an increased risk of virologic failure. This study aims to verify whether drug...